Clinical Investigation Requirements for Medical Devices in Thailand

Not every Class 3 device registration in Thailand requires a Thai clinical investigation, but every device sponsor evaluating that question needs to understand the framework before deciding either way. Thai FDA requires notification and accredited ethics committee approval before a single subject is enrolled at any Thai site, and the standard governing conduct, ISO 14155:2020, applies whether the investigation is being run specifically to support a Thai registration or as one site within a larger global multi-site study.

The regulatory framework and who actually reviews it

Medical device clinical investigations in Thailand are governed by the Medical Device Act B.E. 2562 (2019) and its associated ministerial notifications, with ISO 14155:2020 (Clinical investigation of medical devices for human subjects) as the applicable international standard for how the investigation is designed and conducted. Thai FDA requires investigations to satisfy both the Act's notification requirements and ISO 14155 throughout.

One structural detail sponsors sometimes miss: the Thai FDA's Medical Device Control Division (MDCD) handles device clinical investigation notifications, and this is a separate unit from the division that handles drug clinical trials. Sponsors running parallel drug and device investigations, or investigating a combination product, need to engage both divisions independently rather than assuming one submission covers both. Thailand's device clinical investigation framework is genuinely less mature than its drug trial framework, but Thai FDA has been steadily strengthening oversight as medical device clinical research in the region has grown, and sponsors who assume device investigations get materially lighter scrutiny than drug trials tend to run into compliance problems mid-study or after.

When a Thai investigation is actually required

A device clinical investigation has to be notified to Thai FDA and receive ethics committee approval before enrolling the first subject at any Thai site, whether the study is being conducted specifically to support Thai registration or Thailand is one participating country in a larger global study. Not every Class 3 registration needs Thai-generated data, though. Thai FDA may accept clinical data from investigations conducted entirely outside Thailand, provided the study complied with ISO 14155 (or an equivalent recognized standard such as ICH E6 GCP adapted for devices), the data is relevant to the Thai patient population, and the intended use and patient population studied abroad are consistent with the Thai registration being sought.

Situations where a Thai investigation becomes necessary or strongly preferred include novel device types where Thai FDA has no existing assessment basis to draw on, devices whose intended use involves a procedure not practiced the same way in Thailand, and devices where known ethnic or physiological differences between Thai and foreign populations could plausibly affect safety or performance outcomes.

Working through the notification process

The notification package has to include the clinical investigation plan (functionally the protocol), an Investigational Device Description covering the device's description, intended use, and available safety and performance data, the ethics committee approval letter, Thai-language informed consent form templates, and details of the principal investigator and clinical sites, with every document either in Thai or accompanied by a certified Thai translation. The sponsor or its designated local representative submits this package through Thai FDA's medical device online submission system, and incomplete submissions are returned without a review period ever starting, so the completeness of the initial package matters more than speed in getting something filed. Thai FDA's target review period is typically 30 days from accepted submission, though complex or first-in-class devices commonly take longer, and the sponsor has to wait for Thai FDA's acknowledgment or explicit approval before enrolling any subject.

A parallel ethics committee approval also has to come from a NECAST- (or SIDCER/FERCAP- or AAHRPP-) accredited Institutional Review Board or Independent Ethics Committee, and it has to stay current with whichever protocol version Thai FDA acknowledged. Any protocol amendment requires notifying both Thai FDA and the ethics committee before it's actually implemented, not after the fact.

What ISO 14155 compliance actually looks like in practice

ISO 14155:2020 specifies requirements for the design, conduct, recording, and reporting of clinical investigations assessing a device's clinical performance or safety in human subjects, and Thai FDA expects the clinical investigation report in a registration dossier to include an explicit compliance statement against it. In practice, this means the clinical investigation plan has to follow the structure in ISO 14155 Annex A, covering objectives, design, subject selection criteria, endpoints, statistical analysis, and risk analysis for the investigation itself, since Thai FDA reviewers check the plan against these requirements before accepting the notification at all. Principal and sub-investigators need to be Thailand-licensed healthcare professionals with relevant device and clinical expertise, GCP training, and ideally ISO 14155-specific training if they're new to device investigations specifically. Serious adverse events and device deficiencies that could have led to one have their own reporting clock, distinct from the 10-day window that applies to post-market surveillance once a device is already registered: within a clinical investigation specifically, unanticipated serious adverse device effects must reach Thai FDA within 7 days, a shorter window than sponsors accustomed to drug trial timelines, or to the device's own post-market reporting clock, sometimes expect. Once the investigation concludes, the clinical investigation report has to meet ISO 14155 Annex F requirements, including a full statistical analysis, a benefit-risk evaluation, and a complete summary of adverse events and device deficiencies, since this report becomes the core of the clinical section in the eventual registration dossier.

When foreign clinical data can carry the registration instead

Thai FDA does accept foreign clinical data for Class 3 registration, but acceptance isn't automatic. The dossier needs a bridging justification explaining why the foreign data applies to the Thai patient population and clinical practice context. Three things determine whether that bridging argument holds up. First, the investigation needs to have complied with ISO 14155:2020, ICH E6 (for drug-GCP-managed studies), or an equivalent recognized standard, with the clinical investigation report stating explicitly which standard was applied. Second, the foreign study population has to be genuinely relevant to the Thai population for the intended use; where ethnicity, comorbidities, or clinical management practices differ meaningfully, additional bridging data or a Thai sub-study may be required to close that gap. Third, data that supported a CE marking review, US FDA clearance, or approval by another recognized stringent regulatory authority carries additional weight in Thai FDA's review, though that prior acceptance elsewhere doesn't automatically make it sufficient for Thailand on its own.

What this means for your registration strategy

Deciding whether to run a Thai investigation or rely on existing foreign data is a strategic decision that shapes timeline and cost well before a dossier is assembled, and it's worth making deliberately rather than defaulting to whichever option seems administratively simpler. DeeMED Consulting assesses existing foreign clinical data against Thai FDA's acceptability criteria before dossier preparation begins, and where a Thai investigation is genuinely needed, coordinates notification, ethics committee approval, and investigational device import in parallel as part of building the Thai FDA medical device registration pathway, so the gap between deciding to proceed and enrolling the first Thai patient stays as short as possible.